Lipoprotein (a): Perspectives from a lipid-referral program

Journal of Clinical Lipidology

Volumn 6, Issue 1, 2012, Pages 66-73

  Rubenfire, Melvyn ^a   Vodnala, Deepthi ^a   Krishnan, Sangeetha M ^a   Bard, Robert L ^a   Jackson, Elizabeth A ^a   Giacherio, Donald ^a   Brook, Robert D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Lipid clinic; Lipoprotein (a); Niacin; Predictors; Treatment guidelines

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; FEMALE; GENDER; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCORING SYSTEM;

EID: 84856209736     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.06.009     Document Type: Article

References (30)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report Circulation 106 2002 3143 3421
2. P. Barter, A.M. Gotto, and J.C. LaRosa HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310 (Pubitemid 47481452)
3. F.M. Sacks, P. Alaupovic, and L.A. Moye VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial Circulation 102 16 2000 1886 1892
4. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta- analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219 (Pubitemid 26266496)
5. C.D. Gardner, S.P. Fortmann, and R.M. Krauss Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women JAMA 276 1996 875 881 (Pubitemid 26301606)
6. S. Erqou, S. Kaptoge, and P.L. Perry Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
7. A. Bennet, E. Di Angelantonio, and S. Erqou Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data Arch Intern Med 24 168 2008 598 608 (Pubitemid 351468395)
8. B.G. Nordestgaard, M.J. Chapman, K. Ray for the European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
9. V.V. Brown, C.M. Ballantyne, P.H. Jones, and S. Marcovina Management of Lp(a) J Clin Lipidol 4 2010 240 247
10. S.M. Marcovina, M.L. Koschinsky, J.J. Albers, and S. Skarlatos Report of the National Heart, Lung, and Blood Institute Workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions Clin Chem 49 11 2003 1785 1796 (Pubitemid 37340313)
11. E. Boerwinkle, C.C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H.H. Hobbs Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations J Clin Invest 90 1992 52 60
12. S. Kinlay, A.J. Dobson, R.F. Heller, P. McElduff, H. Alexander, and J. Dickeson Risk of primary and recurrent acute myocardial infarction from lipoprotein(a) in men and women J Am Coll Cardiol 28 1996 870 875 (Pubitemid 26348150)
13. F. Sofi, R. Marcucci, R. Abbate, G.F. Gensini, and D. Prisco Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis Am J Med 120 2007 728 733 (Pubitemid 47189658)
14. M.J. Chapman, J.S. Redfern, M.E. McGovern, and P. Giral Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk Pharmacol Ther 126 2010 314 345
15. M. Okada, H. Matsui, Y. Ito, A. Fujiwara, and K. Inano Low-density lipoprotein cholesterol can be chemically measured: a new superior method J Lab Clin Med 132 1998 195 201 (Pubitemid 28422255)
16. The Emerging Risk Factors Collaboration Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality JAMA 302 2009 412 423
17. K.A. Matthews, M.F. Sowers, C.A. Derby, E. Stein, H. Miracle-McMahill, S.L. Crawford, and R.C. Pasternak Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN) Am Heart J 149 2005 1066 1073 (Pubitemid 40848152)
18. J. Danesh, R. Collins, and R. Peto Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies Circulation 102 2000 1082 1085
19. P.R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard Genetically elevated lipoprotein (a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
20. S. Erqou, A. Thompson, and E. Di Angelantonio Apolipoprotein (a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants J Am Coll Cardiol 55 19 2010 2160 2167
21. E.J. Schaefer, J.J. Genest Jr., J.M. Ordovas, D.N. Salem, and P.W. Wilson Familial lipoprotein disorders and premature coronary artery disease Atherosclerosis 108 Suppl 1994 S41 S54
22. P.J. Schreiner, J.D. Morisett, and A.R. Sharett Lipoprotein(a) as a risk factor for preclinical; atherosclerosis Arterioscler Thromb 13 1993 826 833 (Pubitemid 23164685)
23. F. Dati, J.R. Tate, S.M. Marcovina, and A. Steinmetz First WHO/IFCC international reference reagent for lipoprotein (a) immunoassay: Lp(a) SRM 2B Clin Chem Lab Med 42 2004 670 676 (Pubitemid 38979146)
24. S.A. Murphy, C.P. Cannon, S.D. Wiviott, C.H. McCabe, and E. Braunwald Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial J Am Coll Cardiol 54 2009 2358 2362
25. T.R. Pedersen, O. Faergeman, and J.J. Kastelein Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group: High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445 (Pubitemid 41627921)
26. B.J. Arsenault, P. Barter, D.A. DeMicco for the TNT study Investigators Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients by Lipid and Nonlipid Biomarkers J Am Coll Cardiol 57 2011 63 69
27. E. Bruckert, J. Labreuche, and P. Amarenco Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 2010 353 361
28. J.M. Lee, M.D. Robson, and L.M. Yu Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study J Am Coll Cardiol 54 2009 1787 1794
29. HPT-2 THRIVE. Available at: http://www.ctsu.ox.ac.uk/thrive/ professionals.htm. Accessed June 27, 2011.
30. AIM-HIGH. Niacin Plus Statin to Prevent Vascular Events. Available at: http://clinicaltrials.gov/ct/show/NCT00120289. Accessed June 27, 2011.